Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rivogenlecleucel - Bellicum Pharmaceuticals

Drug Profile

Rivogenlecleucel - Bellicum Pharmaceuticals

Alternative Names: Allogeneic polyclonal T-cells - Bellicum Pharmaceuticals; BPX-501; BPX-501 and AP1903; BPX-501-AP1903; BPX-501-rimiducid; BPX-501-T-cells; CaspaCIDe® DLI; Rimiducid activated BPX 501; Rivo-cel; Rivo-cel - Bellicum Pharmaceuticals

Latest Information Update: 05 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bellicum Pharmaceuticals
  • Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Immunodeficiency disorders; Graft-versus-host disease
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Haematological malignancies; Haemoglobinopathies; Immunodeficiency disorders; Immunological disorders; Metabolic disorders; Myelodysplastic syndromes

Most Recent Events

  • 05 Apr 2024 Discontinued - Phase-I for Haemoglobinopathies (In adolescents, In children, In infants, In adults) in USA (IV) before February 2024 as Bellicum Pharmaceuticals has winded down its business and no longer active
  • 08 Mar 2024 Bellicum Pharmaceuticals terminates a phase I/II follow-up trial in Haematological malignancies (In infants, In children, In adolescents, In adults) in Italy (IV, Infusion) due to unknown reasons, before March 2024 (EudraCT2016-003226-16)
  • 23 Feb 2024 Discontinued - Phase-I for Haematological malignancies (In adolescents, In children, In the elderly, In infants, Second-line therapy or greater, In adults) in USA (IV) before February 2024 as Bellicum Pharmaceuticals has winded down its business and no longer active
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top